/
Oncology
Adenocarcinoma
85
Pipeline Programs↗
87
Active Trials↗
55
Companies Involved↗
Adenocarcinoma is a moderately active landscape with 85 programs across 55 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Biotech Pharmaceutical Co., Ltd.. 22 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 15
Phase 245
Phase 322
Approved
No programs
Analysis
Modality Breakdown
81%
Small molecule
65 of 80 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 80 classified programs, each share of the total. Modality classified for 98% of 85 pipeline programs.
Analysis
Trial Status
294
clinical trials
Completed108 · 37%
Recruiting46 · 16%
Unknown status44 · 15%
Terminated36 · 12%
Not yet recruiting23 · 8%
Active, not recruiting17 · 6%
Other20 · 7%
Clinical Trials
Trial Activity
294 trials
Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma
Recruiting·—·Phase 2·NCT05729646·90 enrolled
Page 1 of 20
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)